| Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2019 | 344 |
| 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer | Journal of Thoracic Oncology | 2019 | 137 |
| Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Journal of Hepatology | 2019 | 106 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Annals of Oncology | 2019 | 101 |
| Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report | Journal of Thoracic Oncology | 2019 | 83 |
| Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies | Cancer | 2019 | 78 |
| Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer | BMC Cancer | 2019 | 68 |
| Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study | Intestinal Research | 2019 | 58 |
| Sequential afatinib and osimertinib in patients with mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology | 2019 | 52 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Annals of Oncology | 2019 | 48 |
| Insights Into Breast Cancer in the East vs the West: A Review | JAMA Oncology | 2019 | 47 |
| Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations | International Journal of Cancer | 2019 | 32 |
| Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers. | Journal of Clinical Oncology | 2019 | 29 |
| Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation | Cell Death and Disease | 2019 | 27 |
| Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment | Liver Cancer | 2019 | 27 |
| Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | Liver International | 2019 | 27 |
| First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression | Journal of Cancer Research and Clinical Oncology | 2019 | 24 |
| A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma | Therapeutic Advances in Medical Oncology | 2019 | 24 |
| Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions | Head and Neck | 2019 | 23 |
| Clinicopathologic Characterization of GREB1-rearranged Uterine Sarcomas With Variable Sex-Cord Differentiation | American Journal of Surgical Pathology | 2019 | 22 |
| Primary cardiac sarcomas: A multi-national retrospective review | Cancer Medicine | 2019 | 21 |
| First-line afatinib for the treatment of mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting | Therapeutic Advances in Medical Oncology | 2019 | 20 |
| Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression | Breast Cancer Research and Treatment | 2019 | 20 |
| Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer | PLoS ONE | 2019 | 18 |
| Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients | European Journal of Cancer | 2019 | 18 |
